The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Smirnova N.F.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnology of the FMBA

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia;
Pirogov City Clinical Hospital No. 1

Latsh N.Yu.

Pirogov National Research Medical University

Treatment of multiple sclerosis with glatiramer acetate: a new look

Authors:

Boyko A.N., Smirnova N.F., Shchukin I.A., Latsh N.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 56‑61

DOI: 10.17116/jnevro202112107256

Views: 3084

Downloaded: 77

Download PDF (RU)
Contact the author
Table of contents

TREATMENT OF MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE: A NEW LOOK
TREATMENT OF MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE: A NEW LOOK

To cite this article:

Boyko AN, Smirnova NF, Shchukin IA, Latsh NYu. Treatment of multiple sclerosis with glatiramer acetate: a new look. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):56‑61. (In Russ.)
https://doi.org/10.17116/jnevro202112107256

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Effi­cacy and safety of choline alfo­scerate in the preventive therapy of deme­ntia in elde­rly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Our expe­rience in the treatment of congenital nasal median hete­rotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32
Clinical and anatomical rationale for the effe­ctiveness of treatment of phle­gmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25

In recent years, the use of a new dosage (40 mg) of glatiramer acetate (GA), which is administered 3 times weekly has become widespread. In Russia, the drug Timexon (produced by the company BIOCAD) was developed and passed successful clinical trials. The final efficacy analysis included 150 patients treated for 12 months. The convenience of using a double dose of GA in 40 mg, which is registered on the territory of the Russian Federation by two manufacturing companies: CJSC BIOCAD and Teva Pharmaceutical Enterprises Ltd., has been proven.

Keywords:

multiple sclerosis
therapy
GA
GA 40 mg

Authors:

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Smirnova N.F.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnology of the FMBA

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia;
Pirogov City Clinical Hospital No. 1

Latsh N.Yu.

Pirogov National Research Medical University

Received:

20.05.2021

Accepted:

21.05.2021

List of references:

  1. Rocco P, Eberini I, Musazzi UM, et al. Glatiramer acetate: A complex drug beyond biologics. Eur J Pharm Sci. 2019;133:8-14.  https://doi.org/10.1016/j.ejps.2019.03.011
  2. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12:543-553.  https://doi.org/10.1016/j.autrev.2012.09.005
  3. Melnikov MV, Sharanova SN, Konovalova OE, et al. The effect of glatiramer acetate on the functioning of Th1 and Th17 cells in patients with multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;8(2):151-158. (In Riss.). https://doi.org/10.17116/jnevro2018118082121
  4. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010;74(suppl 1):25-30. 
  5. Johnson KP, Brooks BR, Ford CC. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6(4):255-266. 
  6. Boyko AN, Davydovskaya MF, Demina TL, et al. Efficacy and tolerability of glatiramer acetate (copaxone) in long-term use: 10-year experience of the Moscow City Center for Multiple Sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;2(2):86-92. (In Russ.). https://doi.org/10.17116/jnevro20151152251-56
  7. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation. Multiple Sclerosis & Demyelinating Diseases. 2016;1:14.  https://doi.org/10.1186/s40893-016-0015-x
  8. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging — measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290-297. 
  9. Signori A, Gallo F, Bovis F, et al. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2016;6:57-63. 
  10. Weinstock-Guttman B, Nair KV, Glajch JL, et al. Two decades of glatiramer acetate: From initial discovery to the current development of generics. J Neurol Sci. 2017;376:255-259. 
  11. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-713. 
  12. Cutter G, Veneziano A, Grinspan A, et al. Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. Mult Scler Relat Disord. 2020;40:101957.
  13. Lasch NU, Boiko AN. Glatiramera aceteta: a review of the results of the GALA and GLACIER clinical trials. Neurology, Psychiatry, Psychosomatics. 2016;8(2):117-120. (In Russ.).
  14. Boyko AN, Lashch NY, Sharanova SN, et al. Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(10 Pt 2):61-67. (In Russ.). https://doi.org/10.17116/jnevro201611610261-67
  15. https://grls.rosminzdrav.ru/
  16. https://www.eapo.org/ru/patents/reestr/patent.php?id=19998 

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.